Mediwound reports second quarter 2024 financial results and provides company update

Completed construction of new nexobrid ® manufacturing facility €16.25 million eic funding expedites escharex ® development for diabetic foot ulcer s , significantly expanding the addressable market ; phase iii study for venous leg ulcers to begin in h2 2024 $25 million strategic investment led by mÖlnlycke health care conference c all t oday, august 14 at 8:30am eastern time yavne, israel, aug. 14, 2024 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended june 30, 2024, and provided a corporate update.
MDWD Ratings Summary
MDWD Quant Ranking